Research suggests that CBD affects certain receptors in the amygdala in the brain, the "fight or flight" area, making this area less excitable. This helps to explain the mechanism by which CBD alleviates anxiety, panic disorder, and PTSD.
In depression, studies have shown decreased quantities of the body's own endocannabinoids and that CBD works like an anti-depressant, increasing 2 neurotransmitters associated with mood - serotonin and norepinephrine.
Research suggests that dysfunction of the endocannabinoid system contributes to many of the core symptoms of autism.
These core symptoms include impairment in social behavior, atypical neural connection development and abnormalities in circadian rhythm and sleep patterns.
Two co-morbidities of autism - anxiety and epilepsy - are also possibly associated with this dysfunctioning system.
Owing to the fact that (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects, the utility of these agents in the treatment of bipolar disorder is logical.
CBD has been shown to increase total sleep time and increase sleep latency (ability to stay asleep).
PTSD is thought to occur as a result of fear memories that replay portions of a traumatic event. CBD has been shown to extinguish what is known as "conditioned fear" through disrupting the formation of fear memories in the brain.
CBD Oil has a pharmacological profile similar to that of atypical antipsychotic drugs, but without the side-effect profile of these potent drugs. Research into the use of Cannabinoids for the treatment of psychosis and schizophrenia is ongoing.